Biopharma likely to climb higher after ‘blue wave,’ analysts say

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 04 Nov, 15:28 UTC

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.

science

Sources

• T2Biopharma likely to climb higher after ‘blue wave,’ analysts sayBioPharma Dive / Healthcare Dive / MedTech Dive04 Nov, 15:28